Search
The American Liver Foundation (ALF) is proud to be a member of Charity at the BMW Berlin Marathon for the 2024 BMW Berlin Marathon, which takes place on Sunday, September 29, 2024. This will be the 50th anniversary of the prestigious event.
Liver disease affects more than 100 million Americans, yet federal investment in early diagnosis, prevention, treatment and research continue to lag far behind other chronic diseases. This summer, American Liver Foundation (ALF) advocates will meet virtually and in-person with elected officials in their local cities and towns to share their liver stories and lend their voices to urge action.
American Liver Foundation (ALF) announces a new Project Echo program for healthcare providers that will bring treatment and prevention best practices for nonalcoholic fatty liver disease (NAFLD)* to non-liver experts.
The Liver Health ECHO Program is a virtual community of practice developed to equip providers with the necessary skills to treat and prevent NAFLD among their patients.
The Liver Health ECHO Program is a virtual community of practice developed to equip providers with the necessary skills to treat and prevent NAFLD among their patients.
The Liver Health ECHO Program is a virtual community of practice developed to equip providers with the necessary skills to treat and prevent NAFLD among their patients.
The Liver Health ECHO Program is a virtual community of practice developed to equip providers with the necessary skills to treat and prevent NAFLD among their patients.
The Liver Health ECHO Program is a virtual community of practice developed to equip providers with the necessary skills to treat and prevent NAFLD among their patients.
Though anyone can be affected, men are more prone to certain types of liver conditions. And while there are many causes […]
This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus.
American Liver Foundation mourns the loss of Col. Stephen A. Harrison, MD, FACP, FAASLD, a revered leader in the field of hepatology, specifically in fatty liver disease (now called steatotic liver disease).
First drug therapy treatment for nonalcoholic steatohepatitis (NASH) provides hopes to millions of Americans